創薬テックMeet Up Sponsored by Danaher Japan～そのアイデアで世界の創薬イノベーションを変える～

平井 昭光（C4U株式会社 代表取締役社長）

1983年に慶應義塾大学法学部法律学科卒業の後司法試験に合格し、 1990年から弁護士として勤務。1993年にバイオテクノロジーと知的財産法について興味を持ち、米国ワシントン大学ロースクールに入学しLL.M.を終了。 米国シアトルにてChristensen O'Connor Johnson Kindness事務所勤務の後帰国し、1996年からはＴＭＩ総合法律事務所勤務。
この頃、文部省及び通商産業省（当時）のTLO法に関する委員会に所属し、産学官連携に関する活動を始める。
その後、さらにバイオテクノロジーのウェットでの研究をすべく、2001年慶応義塾大学大学院医学研究科博士課程（分子生物学専攻）に入学し、その後単位取得退学に至る。
横浜国立大学工学部講師、東北大学客員教授、東京大学講師、東京医科歯科大学客員教授、徳島大学客員教授等大学での教鞭をとる傍ら、バイオベンチャーの役員を多数経験し、その後2009年に株式会社アルファジェン代表取締役として社長を経験し、株式会社ファンペップ代表取締役を経て現在はC4U株式会社代表取締役社長を務める。
ラクオリア創薬株式会社、株式会社ヘリオス、 株式会社ファンペップでは役員としてIPOも経験した。

Samuel Ngai (Head of Danaher Ventures, Asia Vice President, Science & Technology)

Samuel Ngai is the Head of Danaher Ventures in Asia and Global VP of Science & Technology (S&T) at Danaher Corporation. In this capacity, Samuel oversees venture investments and Danaher’s internal and external S&T initiatives across Asia-Pacific. Samuel joined Danaher in late 2018 and founded Danaher’s corporate venture practice in China. Prior to Danaher, Samuel served as the Asia-Pacific Corporate Development and Integration Lead at Thermo Fisher Scientific. Prior to his assignments in Asia, Samuel was a M&A and venture capital professional in Silicon Valley, with experience spanning across US, Europe and Asia. Early in his career, Samuel worked as a strategy consultant in the US health care industry and as a lab researcher at the University of California at San Francisco (UCSF).
Samuel received his M.S. and Ph.D. degrees from Massachusetts Institute of Technology (MIT) and B.S. degree from University of California at Berkeley, all in Biochemical Engineering. Samuel currently serves on MIT’s Graduate Alumni Council and is a board director of the MIT Club of Beijing. From 2018 to 2020, Samuel was the President of the MIT Club of Shanghai. Samuel also serves as the Vice-Chair of the Innovation and Technology Committee at the American Chamber of Commerce in Shanghai. Outside of his corporate and volunteering capacity, Samuel is an advisor and angel investor in early-stage companies.

Ken Horne（Managing Partner, AN Ventures）

Ken Horne is an experienced healthcare investor, entrepreneur and executive with over two decades of professional success. He currently serves as the Managing Partner of AN Ventures, a Japan focused biotech fund. Previously he was the chairperson of RDiscovery, Remiges Ventures’ company creation entity. In this role, he has helped start and invest in Capacity Bio, Typewriter Therapeutics, and Viage Therapeutics as President or CEO. Previously as an entrepreneur, he co-founded or led Aline Aesthetics (acquired by Allergan), Symic Bio (acquired by Nordic Bio), and Teon Therapeutics. Before that, he was a founding member of TauTona Group, an early-stage life science venture capital fund backed by Stanford Management Company and other top LPs. He started his career working for The Foundry, a preeminent medtech incubator, and he was an early or founding employee at eValve (acquired by Abbott), Cierra (acquired by Terumo) and others.
Ken has a BS and MS degree from Stanford University in mechanical engineering, and as a Kauffman Fellow (Class 17) was the Jeff Timmons Leadership Awardee.

塩原 梓（株式会社東京大学エッジキャピタルパートナーズ（UTEC） プリンシパル）　※登壇者が変更になりました。

2021年9月よりUTEC参画。バイオテク、ヘルスケア分野を中心にシード/アーリーステージの投資業務を担当。UTEC参画以前には、アーサー・ディ・リトルにて、ヘルスケアチームのマネジャー。製薬企業・医療機器企業を中心に、新規事業戦略、R&D戦略など様々なプロジェクトに従事。東京大学薬学部卒、同大学院薬学系研究科修了、ロンドン・ビジネス・スクール経営学修了（MBA）。